2003
Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL, Camp RL. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Research 2003, 63: 1101-5. PMID: 12615728.Peer-Reviewed Original ResearchConceptsHepatocyte growth factor activator inhibitor-1Breast carcinomaSeries of proteasesNode-negative breast cancerHigh-level expressionNode-negative breast carcinomaHGF/MET pathwayIndependent prognostic valueBreast cancer progressionPoor patient outcomesTissue microarray analysisPathway componentsMicroarray analysisExtracellular domainActivator inhibitor-1Expression of HGFOverexpression of METMet receptorHepatocyte growth factorCancer progressionMatriptasePrognostic valueBreast markersPatient followPatient outcomes
1999
Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma
Camp R, Rimm E, Rimm D. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999, 86: 2259-2265. PMID: 10590366, DOI: 10.1002/(sici)1097-0142(19991201)86:11<2259::aid-cncr13>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsAxillary lymph node negative breast carcinomaLymph node negative breast carcinomaExpression of METNode-negative breast carcinomaNegative breast carcinomaBreast carcinomaMET expressionMetastatic diseaseRelative riskNegative invasive ductal carcinomaLow Met expressionMET-negative patientsIndependent predictive valueIndependent prognostic markerUseful prognostic indicatorInvasive ductal carcinomaStandard immunoperoxidase techniqueHigh MET expressionHepatocyte growth factorActivation of METAxillary lymphNegative patientsPatient agePrognostic factorsAggressive disease